Bayer chief revives Agfa speculation

Article

Call it the rumor that refused to die. The chairman of Agfa parentBayer has again renewed speculation that the German pharmaceuticalgiant is planning to spin off Agfa into an independent company.In an interview with the German press, Manfred Schneider

Call it the rumor that refused to die. The chairman of Agfa parentBayer has again renewed speculation that the German pharmaceuticalgiant is planning to spin off Agfa into an independent company.In an interview with the German press, Manfred Schneider repeatedstatements made last year that Agfa's profitability is too lowand that Bayer may divest the company in the next several years.

On two occasions last year, Schneider told reporters that therewere few synergies between Bayer and Agfa, because Bayer is apharmaceutical and chemical company and Agfa is moving into digitalimaging, and that Bayer might be interested in selling or divestingAgfa.

Schneider made comments earlier this year that seemed to putthe matter to rest, however, saying that Bayer had no intentionof divesting Agfa (SCAN 2/28/96). He apparently reversed himselflast month, again stating that Agfa's 3% profit margin is toolow compared with the 10% margin the Bayer group is targeting,according to AFX News.

Schneider and Bayer CFO Helmut Loehr said that Bayer would workto improve Agfa's profitability and will decide whether to divestthe company next year. A sale is not likely, due to antitrustconcerns and the probable difficulty in finding a buyer at a priceBayer would find acceptable.

Schneider's most recent comments are nothing new, said DionnTron, Agfa vice president of corporate communications.

"I think that the comments he made were an update on (thesituation). There aren't any intentions to sell Agfa; going publicremains an option," Tron said. "We've been asked toimprove our profitability. We've been working to do that, andwe're beginning to see the results of that effort."

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.